TSCAN THERAPEUTICS, INC.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $10.3M | $2.8M | $21.0M | $13.5M | $10.1M | $1.1M |
| Cost of Revenue | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — |
| Operating Expenses | ||||||
| Research & Development | $114.2M | $107.4M | $88.2M | $59.8M | $45.0M | $20.6M |
| SG&A Expense | $32.0M | $30.3M | $26.4M | $20.4M | $13.8M | $6.7M |
| Operating Income | $-135.8M | $-134.8M | $-93.5M | $-66.6M | $-48.6M | $-26.2M |
| Operating Margin | -1,315.4% | -4,787.7% | -444.0% | -492.3% | -479.6% | -2,417.8% |
| Interest Expense | $2.8M | $3.7M | $3.8M | $1.2M | — | — |
| Pretax Income | — | — | — | — | — | — |
| Income Tax Expense | $0 | — | — | — | — | — |
| Net Income | $-129.8M | $-127.5M | $-89.2M | $-66.2M | $-48.6M | $-26.1M |
| Net Margin | -1,256.8% | -4,527.7% | -423.9% | -489.3% | -479.5% | -2,408.0% |
| EPS (Basic) | $-1.00 | $-1.14 | $-1.36 | $-0.92 | $-0.70 | $-4.75 |
| EPS (Diluted) | $-1.00 | $-1.14 | $-1.36 | $-0.92 | $-0.70 | $-4.75 |
| Shares Outstanding (Basic) | 129.8M | 112.0M | 65.6M | 72.1M | 70.0M | — |
| Shares Outstanding (Diluted) | 129.8M | 112.0M | 65.6M | 72.1M | 70.0M | — |
| Dividends Per Share | — | — | — | — | — | — |